Organisation paid for research Program year 2025 Source: CMS Open Payments

Pulmonix LLC

Neither a doctor nor a teaching hospital

Research payments

$1,702,953

497 payments

Through program year 2025, Pulmonix LLC is reported as receiving $1,702,953 in research payments, across 497 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$329,801	79
2024	Research	$605,403	236
2023	Research	$301,550	108
2022	Research	$202,098	43
2021	Research	$71,158	9
2020	Research	$107,181	8
2019	Research	$85,761	14

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $631,650 149 payments
United Therapeutics Corporation $427,458 249 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $373,726 39 payments
Roche Products Limited $188,051 38 payments
Emergent BioSolutions Inc. $25,428 6 payments
Kadmon Corporation LLC $25,100 5 payments
Regeneron Pharmaceuticals, Inc. $17,000 3 payments
GlaxoSmithKline, LLC. $8,427 2 payments
Hoffmann-La Roche Limited $3,307 3 payments
Sanofi US Services Inc. $2,745 2 payments

Studies the money was for Research payments · program years 2019–2025

Phase 2 Double Blind Randomized Study in IPF and SSc ILD $376,774 68 payments
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $310,795 162 payments
DCRI Registry Study $270,429 13 payments
Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients With Idiopathic Pulmonary Fibrosis $167,151 36 payments
PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $162,269 57 payments
Ph III OLE of Astegolimab in COPD $92,606 24 payments
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $82,635 48 payments
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry $51,807 24 payments
Pulmonary Rehabilitation and Nintedanib in IPF $51,491 2 payments
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) $34,028 39 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.